Format

Send to

Choose Destination
Am J Gastroenterol. 2017 Dec;112(12):1802-1808. doi: 10.1038/ajg.2017.196. Epub 2017 Jul 11.

No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer's Disease.

Author information

1
Kuopio Research Centre of Geriatric Care, University of Eastern Finland, Kuopio, Finland.
2
School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
3
Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, Kuopio, Finland.
4
Research Centre for Comparative Effectiveness and Patient Safety (RECEPS), University of Eastern Finland, Kuopio, Finland.
5
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
6
National Institute for Health and Welfare, Helsinki, Finland.
7
Department of Psychiatry, Kuopio University Hospital, Kuopio, Finland.

Abstract

OBJECTIVES:

The objective of the study was to investigate whether proton pump inhibitor (PPI) use is associated with an increased risk of clinically verified Alzheimer's disease (AD).

METHODS:

A Finnish nationwide nested case-control study MEDALZ includes all community-dwelling individuals with newly diagnosed AD during 2005-2011 (N=70,718), and up to four age-, sex-, and region of residence-matched comparison individuals for each case (N=282,858). Data were extracted from Finnish nationwide health-care registers. PPI use was derived from purchases recorded in the Prescription register data since 1995 and modeled to drug use periods with PRE2DUP method. AD was the outcome measure.

RESULTS:

PPI use was not associated with risk of AD with 3-year lag window applied between exposure and outcome (adjusted odds ratio (OR) 1.03, 95% confidence interval (CI) 1.00-1.05). Similarly, longer duration of use was not associated with risk of AD (1-3 years of use, adjusted OR 1.01 (95% CI 0.97-1.06); ≥3 years of use adjusted OR 0.99 (95% CI 0.94-1.04)). Higher dose use was not associated with an increased risk (≥1.5 defined daily doses per day, adjusted OR 1.03 (95% CI 0.92-1.14)).

CONCLUSIONS:

In conclusion, we found no clinically meaningful association between PPI use and risk of AD. The results for longer duration of cumulative use or use with higher doses did not indicate dose-response relationship.

PMID:
28695906
DOI:
10.1038/ajg.2017.196
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center